Bruker (NASDAQ:BRKR) Price Target Cut to $70.00 by Analysts at TD Cowen

Bruker (NASDAQ:BRKR) had its target price decreased by TD Cowen from $72.00 to $70.00 in a research note released on Wednesday morning,Benzinga reports. TD Cowen currently has a hold rating on the medical research company’s stock.

BRKR has been the subject of several other reports. Wells Fargo & Company reduced their target price on Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research note on Wednesday. The Goldman Sachs Group dropped their price target on Bruker from $72.00 to $60.00 and set a “sell” rating for the company in a report on Tuesday, July 9th. Barclays dropped their price target on Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a report on Wednesday. Citigroup dropped their price target on Bruker from $95.00 to $80.00 and set a “buy” rating for the company in a report on Wednesday, July 10th. Finally, Wolfe Research cut Bruker from an “outperform” rating to a “peer perform” rating in a report on Monday, September 30th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $79.36.

Bruker Stock Performance

Shares of NASDAQ BRKR opened at $57.73 on Wednesday. The company has a current ratio of 1.66, a quick ratio of 0.75 and a debt-to-equity ratio of 1.24. Bruker has a 12 month low of $54.55 and a 12 month high of $94.86. The stock has a 50 day moving average of $63.64 and a 200-day moving average of $66.21. The company has a market capitalization of $8.74 billion, a P/E ratio of 27.75, a P/E/G ratio of 2.83 and a beta of 1.20.

Bruker (NASDAQ:BRKR) last issued its earnings results on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing the consensus estimate of $0.61 by ($0.01). Bruker had a return on equity of 21.52% and a net margin of 9.41%. The business had revenue of $864.40 million for the quarter, compared to the consensus estimate of $866.46 million. During the same quarter in the prior year, the firm posted $0.74 earnings per share. The business’s revenue was up 16.4% compared to the same quarter last year. As a group, equities research analysts predict that Bruker will post 2.39 EPS for the current year.

Hedge Funds Weigh In On Bruker

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC raised its holdings in Bruker by 20.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 991 shares of the medical research company’s stock valued at $63,000 after acquiring an additional 165 shares in the last quarter. Securian Asset Management Inc. raised its holdings in Bruker by 2.3% in the 2nd quarter. Securian Asset Management Inc. now owns 7,766 shares of the medical research company’s stock valued at $496,000 after acquiring an additional 175 shares in the last quarter. Covestor Ltd raised its holdings in shares of Bruker by 139.1% during the 1st quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock worth $34,000 after buying an additional 210 shares in the last quarter. First Horizon Advisors Inc. raised its holdings in shares of Bruker by 120.4% during the 2nd quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock worth $25,000 after buying an additional 218 shares in the last quarter. Finally, Ameritas Investment Partners Inc. raised its holdings in shares of Bruker by 0.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 30,911 shares of the medical research company’s stock worth $1,972,000 after buying an additional 235 shares in the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.